We report the final analysis of the Drep-Haplo multicenter phase 2 protocol, which evaluated haploidentical transplantation after reduced-intensity conditioning regimen incorporating thiotepa, in children and adults with severe sickle cell disease (SCD). Twenty-two patients (median age: 17 years; range: 12–40) received a conditioning regimen consisting of 2 Gy total body irradiation, thymoglobulin, cyclophosphamide, fludarabine, and thiotepa, followed by T cell–replete bone marrow infusion and graft-versus-host disease (GVHD) prophylaxis based on post-transplant cyclophosphamide. The primary endpoint, event-free survival, defined as survival without graft failure and without moderate-to-severe chronic GVHD, was 68.18% (95% CI: 51.25%–90.70%) and 61.98% (95% CI: 44.07%–87.19%) at 1 and 4 years, respectively. Overall survival and rejection-free survival at 4 years were 90.15% (95% CI: 78.03%–100%) and 85.56% (95% CI: 71.63%–100%), respectively. Six patients (27%) developed moderate-to-severe GVHD. In most cases (4/6), GVHD resolved, leaving only two patients (9%) with persistent moderate to severe GVHD at last follow-up. Eighty-five grade 2 to 4 infectious episodes were reported in 21 patients during the 24 months of follow-up, most of which were bacterial (38 cases). These data strengthen existing evidence supporting the feasibility of haploidentical transplantation in both pediatric and adult patients with severe SCD, demonstrating a very low rejection rate when thiotepa is incorporated into the conditioning regimen. Future efforts should focus on reducing chronic GVHD and infection rates.
Dhédin et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: